Infectious pulmonary complications in patients treated with anti-TNF-α monoclonal antibodies and soluble TNF receptor-Reference-Cited by-同舟云学术

Infectious pulmonary complications in patients treated with anti-TNF-α monoclonal antibodies and soluble TNF receptor

Published:2009-04-18 Issue:3 Volume:11 Page:229-236
ISSN:1523-3847
Container-title:Current Infectious Disease Reports
language:en
Short-container-title:Curr Infect Dis Rep

Author:

Carbone Javier,Perez-Rojas Javier,Sarmiento Elizabeth

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1007/s11908-009-0034-2.pdf

Reference50 articles.

1. Lin J, Ziring D, Desai S, et al.: TNFa blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13–30.

2. Furst DE: The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2008 (Epub ahead of print).

3. Yamamura M: Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis—efficacy evaluation, adverse effect detection, and prediction of clinical response. Nippon Rinsho 2007, 65:1269–1275.

4. Saliu OY, Sofer C, Stein DS, et al.: Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194:486–492.

5. Harris J, Hope JC, Keane J: Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis 2008, 198:1842–1850.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Polymeric Nano-Materials in Management of Inflammatory Bowel Disease;Current Topics in Medicinal Chemistry;2020-06-01

2. Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation;Nature Communications;2018-04-10

3. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model;Health Technology Assessment;2016-05

4. Connective Tissue Disease–Associated Lung Disease;Immunology and Allergy Clinics of North America;2012-11

5. Pulmonary Infections in the Era of Biological Agents;Current Respiratory Medicine Reviews;2012-07-01